Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis

Launched by ELI LILLY AND COMPANY · May 31, 2024

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Self-report being diagnosed with atopic dermatitis (AD) by a physician and able to provide approximate diagnosis date.
• • Autoinjector or Pen naïve \[have not used an autoinjector or pen previously; permissible to have used a pre-filled syringe (PFS) or vial and syringe\].
• • Willing and able to attend an in-person interview session.
• • Able to complete the protocol requirements.
• Exclusion Criteria:
• • Cognitive or physical difficulties that could interfere with ability to understand the training, perform the injection tasks, or complete the study questionnaires as judged by the investigator.
• • Are currently enrolled or have participated in the last 3 months, in a clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
• • Is a health care practitioner who is trained in giving injections.
• • Currently pregnant.
• • Known hypersensitivity to any component of lebrikizumab or its excipients.
• • Treatment with a live (or live attenuated) vaccine within the past 12 weeks.
• • Current or chronic infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) per participant self-report.

Trial Officials